Literature DB >> 21130128

A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5).

Anna Kaźmierczak1, Grzegorz A Czapski, Agata Adamczyk, Barbara Gajkowska, Joanna B Strosznajder.   

Abstract

The non-Aβ component of Alzheimer's disease (AD) amyloid (NAC) is produced from the precursor protein NACP/α-synuclein (ASN) by till now unknown mechanism. Previous study showed that like ASN, NAC peptide induced oxidative/nitrosative stress and apoptosis. Our present study focused on the mechanisms of PC12 cells death evoked by NAC peptide, with particular consideration on the role of p53 protein. On the basis of molecular and transmission electron microscopic (TEM) analysis it was found that exogenous NAC peptide (10 μM) caused mitochondria dysfunction, enhanced free radical generation, and induced both apoptotic and autophagic cell death. Morphological and immunocytochemical evidence from TEM showed marked changes in expression and in translocation of proapoptotic protein Bax. We also observed time-dependent enhancement of Tp53 gene expression after NAC treatment. Free radicals scavenger N-tert-butyl-alpha-phenylnitrone (PBN, 1 mM) and p53 inhibitor (α-Pifithrin, 20 μM) significantly protected PC12 cells against NAC peptide-evoked cell death. In addition, exposure to NAC peptide resulted in higher expression of cyclin-dependent kinase 5 (Cdk5), one of the enzymes responsible for p53 phosphorylation and activation. Concomitantly, we observed the increase of expression of Cdk5r1 and Cdk5r2 genes, coding p35 and p39 peptides that are essential regulators of Cdk5 activity. Moreover, the specific Cdk5 inhibitor (BML-259, 10 μM) protected large population of cells against NAC-evoked cell death. Our findings indicate that NAC peptide exerts its toxic effect by activation of p53/Cdk5 and Bax-dependent apoptotic signaling pathway. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21130128     DOI: 10.1016/j.neuint.2010.11.018

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  7 in total

1.  Cyclin-dependent kinase 5 represses Foxp3 gene expression and Treg development through specific phosphorylation of Stat3 at Serine 727.

Authors:  Eric Lam; Sung Hee Choi; Tej K Pareek; Byung-Gyu Kim; John J Letterio
Journal:  Mol Immunol       Date:  2015-07-19       Impact factor: 4.407

2.  p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells.

Authors:  Eleonora Da Pozzo; Valeria La Pietra; Barbara Cosimelli; Federico Da Settimo; Chiara Giacomelli; Luciana Marinelli; Claudia Martini; Ettore Novellino; Sabrina Taliani; Giovanni Greco
Journal:  ACS Chem Neurosci       Date:  2014-03-28       Impact factor: 4.418

3.  Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity.

Authors:  Anna Wilkaniec; Magdalena Gąssowska-Dobrowolska; Marcin Strawski; Agata Adamczyk; Grzegorz A Czapski
Journal:  J Neuroinflammation       Date:  2018-01-04       Impact factor: 8.322

Review 4.  Neurometals in the Pathogenesis of Prion Diseases.

Authors:  Masahiro Kawahara; Midori Kato-Negishi; Ken-Ichiro Tanaka
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

5.  The Molecular Mechanism of Amyloid β42 Peptide Toxicity: The Role of Sphingosine Kinase-1 and Mitochondrial Sirtuins.

Authors:  Magdalena Cieślik; Grzegorz A Czapski; Joanna B Strosznajder
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

Review 6.  Selenium in the Therapy of Neurological Diseases. Where is it Going?

Authors:  Agnieszka Dominiak; Anna Wilkaniec; Piotr Wroczyński; Agata Adamczyk
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

7.  Genetic networks in Parkinson's and Alzheimer's disease.

Authors:  Jack Kelly; Rana Moyeed; Camille Carroll; Shouqing Luo; Xinzhong Li
Journal:  Aging (Albany NY)       Date:  2020-03-23       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.